Head and Neck Squamous Cell Carcinoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Merck Sharp & Dohme Corp., Sinocelltech Ltd., Hoffmann-La Roche

May 01 16:28 2023
Head and Neck Squamous Cell Carcinoma Market: Analysis of Epidemiology, Pipeline Products, and Key Companies Working in the Market | Merck Sharp & Dohme Corp., Sinocelltech Ltd., Hoffmann-La Roche
Head and Neck Squamous Cell Carcinoma Market
DelveInsight’s “Head and Neck Squamous Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Head and Neck Squamous Cell Carcinoma, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight has launched a new report on “Head and Neck Squamous Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2032”.

DelveInsight’s “Head and Neck Squamous Cell Carcinoma – Market Insights, Epidemiology, and Market Forecast-2032″ report delivers an in-depth understanding of the Head and Neck Squamous Cell Carcinoma, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Some of the key facts of the Head and Neck Squamous Cell Carcinoma Market Report:

  1. According to an Organization, 2014, The annual incidence of head and neck cancers worldwide is more than 550,000 cases with around 300,000 deaths each year. The male to female ratio ranges from 2:1 to 4:1. About 90% of all head and neck cancers are squamous cell carcinomas. 
  2. SCC is the most frequent malignant tumor of the head and neck region. HNSCC represents the sixth leading cancer by incidence and there are 500,000 new cases a year worldwide (Kamangar et al., 2006). 

Key benefits of the report:

  1. Head and Neck Squamous Cell Carcinoma  market report covers a descriptive overview and comprehensive insight of the Head and Neck Squamous Cell Carcinoma  Epidemiology and Head and Neck Squamous Cell Carcinoma  market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
  2. The Head and Neck Squamous Cell Carcinoma market report provides insights on the current and emerging therapies.
  3. Head and Neck Squamous Cell Carcinoma market report provides a global historical and forecasted market covering drug outreach in 7MM.
  4. The Head and Neck Squamous Cell Carcinoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Head and Neck Squamous Cell Carcinoma market.

Got queries? Click here to know more about the Head and Neck Squamous Cell Carcinoma Market Landscape.

Head and Neck Squamous Cell Carcinoma Overview

Head and neck cancer is a term used to define cancer that develops in the mouth (oral cavity), throat, nose, salivary glands, oral cancers, or other areas of the head and neck. Most of these are classified as squamous cases which cover 90% of the disease area. The causes of head and neck cancers are not fully understood. There are certain risk factors that increase the risk of developing the disease such as smoking tobacco, consumption of alcohol, and exposure to the human papillomavirus (HPV) which contributes to the development of at least 90% of squamous cell carcinoma of the head and neck. At least 12% of pharyngeal cancer, 3% of oral cancer, and 30–60% of oropharyngeal carcinoma cases are caused by HPV infection.

Head and Neck Squamous Cell Carcinoma Market 

The dynamics of the Head and Neck Squamous Cell Carcinoma market is anticipated to change in the coming years owing to the expected launch of emerging therapies such as Lenvatinib (E7080/MK-7902) (Merck Sharp & Dohme Corp.), SCT-I10A+Chemo (Sinocelltech Ltd.), Atezolizumab (Hoffmann-La Roche), Ficlatuzumab (AVEO Pharmaceuticals, Inc.), Evorpacept (ALX Oncology) and others during the forecasted period 2022-2032.

Learn more by requesting for sample @ Head and Neck Squamous Cell Carcinoma Market Landscape 

Head and Neck Squamous Cell Carcinoma Pipeline Therapies and Key Companies 

  • Lenvatinib (E7080/MK-7902) : Merck Sharp & Dohme Corp.
  • SCT-I10A+Chemo : Sinocelltech Ltd.
  • Atezolizumab : Hoffmann-La Roche
  • Ficlatuzumab: AVEO Pharmaceuticals, Inc.
  • Evorpacept: ALX Oncology, and others

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Head and Neck Squamous Cell Carcinoma Patient Share (%) Overview at a Glance

5. Head and Neck Squamous Cell Carcinoma Market Overview at a Glance

6. Head and Neck Squamous Cell Carcinoma Disease Background and Overview

7. Head and Neck Squamous Cell Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Head and Neck Squamous Cell Carcinoma 

9. Head and Neck Squamous Cell Carcinoma Current Treatment and Medical Practices

10. Unmet Needs

11. Head and Neck Squamous Cell Carcinoma Emerging Therapies

12. Head and Neck Squamous Cell Carcinoma Market Outlook

13. Country-Wise Head and Neck Squamous Cell Carcinoma Market Analysis (2019–2032)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Head and Neck Squamous Cell Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/